Published in Brain Res on December 20, 2006
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol (2007) 3.19
Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. Clin Microbiol Rev (2009) 1.49
High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke (2010) 1.30
Reversal of West Nile virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor. Virology (2009) 1.25
Pharmacological stabilization of intracranial aneurysms in mice: a feasibility study. Stroke (2012) 1.10
Increased cerebral matrix metalloprotease-9 activity is associated with compromised recovery in the diabetic db/db mouse following a stroke. J Neurochem (2011) 0.92
Differential response of primary alveolar type I and type II cells to LPS stimulation. PLoS One (2013) 0.88
Normobaric hyperoxia combined with minocycline provides greater neuroprotection than either alone in transient focal cerebral ischemia. Exp Neurol (2012) 0.87
Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiol Dis (2015) 0.84
Astrocyte-derived thrombospondin-2 is critical for the repair of the blood-brain barrier. Am J Pathol (2011) 0.83
Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature. Invest Radiol (2008) 0.78
Cerebral ischemic damage in diabetes: an inflammatory perspective. J Neuroinflammation (2017) 0.78
Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis. BMC Infect Dis (2014) 0.76
Serum matrix metalloproteinase-9 levels and severity of symptoms in boys with attention deficit hyperactivity disorder ADHD/hyperkinetic disorder HKD. Eur Child Adolesc Psychiatry (2014) 0.75
Fusion Peptides CPU1 and CPU2 Inhibit Matrix Metalloproteinases and Protect Mice from Endotoxin Shock Within a Strict Time Window. Inflammation (2015) 0.75
Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer (2002) 5.57
Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med (2006) 5.10
Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol (2000) 4.98
Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med (2000) 4.18
A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A (1999) 3.96
Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci (2001) 3.71
Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke (1998) 3.58
The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci (2002) 3.55
Matrix metalloproteinases in neuroinflammation. Glia (2002) 3.51
Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem (1994) 3.37
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain (2005) 2.12
Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain (2002) 2.00
Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol (2003) 1.93
Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci (2006) 1.85
Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest (1994) 1.82
Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke (2000) 1.71
Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis (2006) 1.68
Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain (2001) 1.65
Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev (2001) 1.59
Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol (1978) 1.43
Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol (1998) 1.39
The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues. Neuroscience (1992) 1.28
Zymographic measurement of gelatinase activity in brain tissue after detergent extraction and affinity-support purification. J Neurosci Methods (1997) 1.19
Quantitative evaluation of the effect of propylene glycol on BBB permeability. J Magn Reson Imaging (2007) 1.04
Stromelysin-1 and gelatinase A are upregulated before TNF-alpha in LPS-stimulated neuroinflammation. Brain Res (2002) 1.01
Effects of intravenous dimethyl sulfoxide on ischemia evolution in a rat permanent occlusion model. J Cereb Blood Flow Metab (2005) 0.92
The inflammatory response in the CNS. Neuropathol Appl Neurobiol (1992) 0.87
Diazoxide and dimethyl sulphoxide alleviate experimental cerebral hypoperfusion-induced white matter injury in the rat brain. Neurosci Lett (2004) 0.85
Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev (2005) 4.48
Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab (2006) 4.19
Tackling antibiotic resistance. Nat Rev Microbiol (2011) 3.95
Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev (2003) 3.72
Three-dimensional structure of the bacterial cell wall peptidoglycan. Proc Natl Acad Sci U S A (2006) 2.81
A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci (2005) 2.54
Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res (2008) 1.88
Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem (2005) 1.83
How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc Natl Acad Sci U S A (2013) 1.75
The basis for resistance to beta-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. J Biol Chem (2004) 1.74
Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis (2006) 1.68
Ab initio QM/MM study of class A beta-lactamase acylation: dual participation of Glu166 and Lys73 in a concerted base promotion of Ser70. J Am Chem Soc (2005) 1.67
Recent advances in MMP inhibitor design. Cancer Metastasis Rev (2006) 1.66
Bacterial cell-wall recycling. Ann N Y Acad Sci (2012) 1.60
Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge. Antimicrob Agents Chemother (2009) 1.51
Design and characterization of a metalloproteinase inhibitor-tethered resin for the detection of active MMPs in biological samples. Chem Biol (2006) 1.50
Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J Am Chem Soc (2008) 1.50
Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev (2003) 1.45
Aminoglycosides modified by resistance enzymes display diminished binding to the bacterial ribosomal aminoacyl-tRNA site. Chem Biol (2002) 1.42
Resistance to beta-lactam antibiotics and its mediation by the sensor domain of the transmembrane BlaR signaling pathway in Staphylococcus aureus. J Biol Chem (2003) 1.38
Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res (2005) 1.36
The future of the β-lactams. Curr Opin Microbiol (2010) 1.36
High-resolution X-ray structure of an acyl-enzyme species for the class D OXA-10 beta-lactamase. J Am Chem Soc (2002) 1.36
Synthetic peptidoglycan substrates for penicillin-binding protein 5 of Gram-negative bacteria. J Org Chem (2004) 1.33
Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM beta-lactamase. Biochemistry (2005) 1.32
Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer (2006) 1.32
Bacterial AmpD at the crossroads of peptidoglycan recycling and manifestation of antibiotic resistance. J Am Chem Soc (2009) 1.31
Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J Cereb Blood Flow Metab (2007) 1.30
Activation of BlaR1 protein of methicillin-resistant Staphylococcus aureus, its proteolytic processing, and recovery from induction of resistance. J Biol Chem (2011) 1.30
Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther (2007) 1.29
Mechanistic characterization of the bifunctional aminoglycoside-modifying enzyme AAC(3)-Ib/AAC(6')-Ib' from Pseudomonas aeruginosa. Biochemistry (2007) 1.28
Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of beta-lactamases. J Biol Chem (2009) 1.28
Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. J Biol Chem (2013) 1.27
Structural insights into the bactericidal mechanism of human peptidoglycan recognition proteins. Proc Natl Acad Sci U S A (2007) 1.27
Extracellular proteases as targets for treatment of cancer metastases. Chem Soc Rev (2004) 1.26
Characterization of the bifunctional aminoglycoside-modifying enzyme ANT(3'')-Ii/AAC(6')-IId from Serratia marcescens. Biochemistry (2006) 1.25
Mechanism of anchoring of OmpA protein to the cell wall peptidoglycan of the gram-negative bacterial outer membrane. FASEB J (2011) 1.25
Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 beta-lactamase confers increased MIC of cefepime. Antimicrob Agents Chemother (2002) 1.23
Design of novel antibiotics that bind to the ribosomal acyltransfer site. J Am Chem Soc (2002) 1.23
The importance of a critical protonation state and the fate of the catalytic steps in class A beta-lactamases and penicillin-binding proteins. J Biol Chem (2004) 1.22
Activation for catalysis of penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus by bacterial cell wall. J Am Chem Soc (2005) 1.22
Reactions of all Escherichia coli lytic transglycosylases with bacterial cell wall. J Am Chem Soc (2013) 1.21
Source of phosphate in the enzymic reaction as a point of distinction among aminoglycoside 2''-phosphotransferases. J Biol Chem (2009) 1.21
Lytic transglycosylase MltB of Escherichia coli and its role in recycling of peptidoglycan strands of bacterial cell wall. J Am Chem Soc (2008) 1.21
Synthesis of a fragment of bacterial cell wall. J Org Chem (2004) 1.20
Total synthesis of N-acetylglucosamine-1,6-anhydro-N-acetylmuramylpentapeptide and evaluation of its turnover by AmpD from Escherichia coli. J Am Chem Soc (2009) 1.19
Molecular structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the cysteine switch dogma. J Am Chem Soc (2007) 1.19
The complex of a designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography. J Am Chem Soc (2003) 1.18
Three decades of the class A beta-lactamase acyl-enzyme. Curr Protein Pept Sci (2009) 1.17
Discrete steps in sensing of beta-lactam antibiotics by the BlaR1 protein of the methicillin-resistant Staphylococcus aureus bacterium. Proc Natl Acad Sci U S A (2006) 1.17
Messenger functions of the bacterial cell wall-derived muropeptides. Biochemistry (2012) 1.17
X-ray crystal structure of the acylated beta-lactam sensor domain of BlaR1 from Staphylococcus aureus and the mechanism of receptor activation for signal transduction. J Am Chem Soc (2004) 1.15
Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J Neurochem (2009) 1.15
Early inhibition of MMP activity in ischemic rat brain promotes expression of tight junction proteins and angiogenesis during recovery. J Cereb Blood Flow Metab (2013) 1.12
Synthetic peptidoglycan motifs for germination of bacterial spores. Chembiochem (2010) 1.12
Complex pattern of membrane type 1 matrix metalloproteinase shedding. Regulation by autocatalytic cells surface inactivation of active enzyme. J Biol Chem (2002) 1.12
Disruption of allosteric response as an unprecedented mechanism of resistance to antibiotics. J Am Chem Soc (2014) 1.11
Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases. Chem Biol Drug Des (2009) 1.11
Roles of matrix metalloproteinases in flow-induced outward vascular remodeling. J Cereb Blood Flow Metab (2009) 1.10
Metabolism of a highly selective gelatinase inhibitor generates active metabolite. Chem Biol Drug Des (2007) 1.10
Discovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity. J Am Chem Soc (2014) 1.10
Pharmacological stabilization of intracranial aneurysms in mice: a feasibility study. Stroke (2012) 1.10
Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol Neurodegener (2012) 1.10
Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol (2007) 1.09
Insertion of epicatechin gallate into the cytoplasmic membrane of methicillin-resistant Staphylococcus aureus disrupts penicillin-binding protein (PBP) 2a-mediated beta-lactam resistance by delocalizing PBP2. J Biol Chem (2010) 1.09
Short alkylated peptoid mimics of antimicrobial lipopeptides. Antimicrob Agents Chemother (2010) 1.08
Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. Org Lett (2005) 1.08
Molecular dynamics at the root of expansion of function in the M69L inhibitor-resistant TEM beta-lactamase from Escherichia coli. J Am Chem Soc (2002) 1.08
Structural basis for carbapenemase activity of the OXA-23 β-lactamase from Acinetobacter baumannii. Chem Biol (2013) 1.08
Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity. J Biol Chem (2004) 1.07
A practical synthesis of nitrocefin. J Org Chem (2005) 1.07
Reactions of the three AmpD enzymes of Pseudomonas aeruginosa. J Am Chem Soc (2013) 1.06
Elucidation of the molecular recognition of bacterial cell wall by modular pneumococcal phage endolysin CPL-1. J Biol Chem (2007) 1.06
Crystal structures of penicillin-binding protein 6 from Escherichia coli. J Am Chem Soc (2009) 1.05
Quantitative evaluation of the effect of propylene glycol on BBB permeability. J Magn Reson Imaging (2007) 1.04
Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J Biol Chem (2002) 1.04
Matrix metalloproteinase 2 inhibition: combined quantum mechanics and molecular mechanics studies of the inhibition mechanism of (4-phenoxyphenylsulfonyl)methylthiirane and its oxirane analogue. Biochemistry (2009) 1.04
Phosphoryl transfer by aminoglycoside 3'-phosphotransferases and manifestation of antibiotic resistance. Bioorg Chem (2004) 1.03
Lysine N(zeta)-decarboxylation in the BlaR1 protein from Staphylococcus aureus at the root of its function as an antibiotic sensor. J Am Chem Soc (2007) 1.03
Kinetic mechanism of enterococcal aminoglycoside phosphotransferase 2"-Ib. Biochemistry (2007) 1.02
Catalytic mechanism of penicillin-binding protein 5 of Escherichia coli. Biochemistry (2007) 1.02
Insights into pneumococcal fratricide from the crystal structures of the modular killing factor LytC. Nat Struct Mol Biol (2010) 1.01
Increased apparent diffusion coefficients on MRI linked with matrix metalloproteinases and edema in white matter after bilateral carotid artery occlusion in rats. J Cereb Blood Flow Metab (2008) 1.01
A potent gelatinase inhibitor with anti-tumor-invasive activity and its metabolic disposition. Chem Biol Drug Des (2009) 1.00
Crystal structures of bacterial peptidoglycan amidase AmpD and an unprecedented activation mechanism. J Biol Chem (2011) 1.00
Shedding of discoidin domain receptor 1 by membrane-type matrix metalloproteinases. J Biol Chem (2013) 1.00
Mechanistic basis for the action of new cephalosporin antibiotics effective against methicillin- and vancomycin-resistant Staphylococcus aureus. J Biol Chem (2006) 1.00
Resistance to the third-generation cephalosporin ceftazidime by a deacylation-deficient mutant of the TEM β-lactamase by the uncommon covalent-trapping mechanism. Biochemistry (2011) 1.00
Crystal structure of CbpF, a bifunctional choline-binding protein and autolysis regulator from Streptococcus pneumoniae. EMBO Rep (2009) 0.99
Interactions of designer antibiotics and the bacterial ribosomal aminoacyl-tRNA site. Chem Biol (2006) 0.98
Investigation of the mechanism of the cell wall DD-carboxypeptidase reaction of penicillin-binding protein 5 of Escherichia coli by quantum mechanics/molecular mechanics calculations. J Am Chem Soc (2008) 0.98
Selective inhibition of matrix metalloproteinase-9 attenuates secondary damage resulting from severe traumatic brain injury. PLoS One (2013) 0.98
Quest for selectivity in inhibition of matrix metalloproteinases. Curr Top Med Chem (2004) 0.97
Structural basis for potent slow binding inhibition of human matrix metalloproteinase-2 (MMP-2). J Biol Chem (2003) 0.97
Dissection of events in the resistance to β-lactam antibiotics mediated by the protein BlaR1 from Staphylococcus aureus. Biochemistry (2012) 0.97
The bifunctional enzymes of antibiotic resistance. Curr Opin Microbiol (2009) 0.96
A computational evaluation of the mechanism of penicillin-binding protein-catalyzed cross-linking of the bacterial cell wall. J Am Chem Soc (2011) 0.96
Spatiotemporal correlations between blood-brain barrier permeability and apparent diffusion coefficient in a rat model of ischemic stroke. PLoS One (2009) 0.96
Recognition of peptidoglycan and β-lactam antibiotics by the extracellular domain of the Ser/Thr protein kinase StkP from Streptococcus pneumoniae. FEBS Lett (2010) 0.96
Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem (2005) 0.96